Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and efficacy of a novel nucleoside sparing regimen containing atazanavir, ritonavir and efavirenz, using two different doses of atazanavir.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bristol-Myers Squibb
NCT06694805 · HIV Infections
NCT06627764 · Substance Abuse, Intimate Partner Violence (IPV), and more
NCT04142047 · HIV, HIV Infections
NCT05398185 · HIV Infections, Acquired Immune Deficiency Syndrome, and more
NCT07428330 · Cervix Cancer, HIV Infections, and more
Local Institution
San Francisco, California
Local Institution
Washington D.C., District of Columbia
Local Institution
Atlantis, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions